Company news
Galectin Therapeutics Inc. (NASDAQ:GALT) news
Galectin Therapeutics Inc. news releases on 6ix. Latest, Oct 6, 2026: Galectin Therapeutics to Present at the American Association for the Study of Liver…
Press releases & updates
Galectin Therapeutics to Present at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting 2026
October 6, 2026
Galectin Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
September 10, 2026
Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update
August 14, 2026
Galectin Therapeutics Announces Conversion of $105.8 Million in Debt to Equity, Significantly Strengthening Balance Sheet
August 4, 2026
Galectin Therapeutics Announces Positive Type C Meeting with the FDA for Belapectin in Patients with MASH Cirrhosis and Portal Hypertension
June 22, 2026
Galectin Therapeutics Presents New EASL 2026 Oral and Poster Analyses Demonstrating Belapectin’s Potential to Modify Disease Progression in Advanced MASH Cirrhosis
May 27, 2026
Galectin Therapeutics Reports March 31, 2026 Financial Results and Provides Business Update
May 15, 2026
Galectin Therapeutics Announces Publication of NAVIGATE Phase 2b Trial Results for Belapectin in the Journal of Hepatology
May 10, 2026
Galectin Therapeutics Reports 2025 Financial Results and Provides Business Update
March 30, 2026
Galectin Therapeutics Strengthens Board of Directors with Appointment of Henry Brem, M.D.
March 16, 2026
Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin Development Program for Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) Cirrhosis and Portal Hypertension, on March 10, 2026 at 12:00 PM ET
February 26, 2026
Galectin Therapeutics Provides Regulatory Update Following FDA Written Response and Announces an Additional $10 Million Line of Credit from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through March 2027
December 19, 2025
Galectin Therapeutics Reports Financial Results for the quarter ended September 30, 2025, and Provides Business Update
November 14, 2025
Galectin Therapeutics Presented NAVIGATE Trial Results at the American Association for the Study of Liver Diseases (AASLD) 2025 Annual Meeting
November 10, 2025
Galectin Therapeutics to Present at the H.C. Wainwright 9th Annual MASH Investor Conference
October 19, 2025
Galectin Therapeutics to Present at the American Association for the Study of Liver Disease (AASLD) Liver Meeting 2025
October 7, 2025
Galectin Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
September 2, 2025
Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2025 and Provides Business Update
August 14, 2025
Galectin Therapeutics Announces New $10 Million Credit Line from Richard E. Uihlein, Sufficient to Cover Expected Expenditures Through June 2026
July 9, 2025
Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin for Treatment of MASH Cirrhosis and Portal Hypertension
June 10, 2025
Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2025 and Provides Business Update
May 15, 2025
Galectin Therapeutics Presented NAVIGATE Trial Results at the European Association for the Study of the Liver (EASL) 2025 Congress
May 12, 2025
Galectin Therapeutics to Present at the European Association for the Study of the Liver (EASL) 2025 Congress
April 15, 2025
Galectin Therapeutics Reports 2024 Financial Results and Provides Business Update
March 31, 2025
Galectin Therapeutics Reports Significant Reduction in New Varices with Belapectin in U.S. Patient Population from the NAVIGATE Trial
February 18, 2025
Galectin Therapeutics to Present at the 2025 MASH-TAG Conference
January 9, 2025
Galectin Therapeutics Announces Top-Line Results of NAVIGATE Clinical Trial Evaluating Belapectin in Patients with Cirrhotic Portal Hypertension Caused by MASH
December 19, 2024
Galectin Therapeutics Presents Three Abstracts at the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting
November 17, 2024
Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2024 and Provides Business Update
November 13, 2024
Galectin Therapeutics Announces Acceptance of Three Abstracts for the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting
October 14, 2024
Galectin Therapeutics to Participate in the H.C. Wainwright MASH Conference
September 29, 2024
Galectin Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
September 2, 2024
Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2024 and Provides Business Update
August 12, 2024
Galectin Therapeutics Appoints Khurram Jamil, M.D. to Chief Medical Officer
July 31, 2024
Galectin Therapeutics to Present at the European Association for the Study of the Liver (EASL) 2024 Congress
June 3, 2024
Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2024 and Provides Business Update
May 14, 2024
Galectin Therapeutics to Participate in the H.C. Wainwright BioConnect Conference
May 12, 2024
Galectin Therapeutics Reports the Positive Outcome of the Fifth Data and Safety Monitoring Board Meeting for NAVIGATE Phase 2b/3 Study of Belapectin in Patients with Cirrhotic Portal Hypertension Caused by Metabolic Dysfunction-Associated SteatoHepatitis
April 8, 2024
Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update
March 28, 2024
Galectin Therapeutics Expands Clinical Team with the Appointment of Khurram Jamil, M.D. as Vice President, Clinical Development
March 11, 2024
Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update
November 12, 2023
Galectin Therapeutics to Share Five Scientific Presentations at The Liver Meeting™ 2023, Hosted by the AASLD
November 2, 2023
Galectin Therapeutics to Participate in the H.C. Wainwright 7th Annual NASH Investor Conference on October 24, 2023
October 22, 2023
Galectin Therapeutics Announces Nomination of Dr. Benjamin S. Carson, Sr. to Board of Directors
October 11, 2023
Galectin Therapeutics Reports the Positive Outcome of the Fourth Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Portal Hypertension Caused by Non-Alcoholic SteatoHepatitis ...
October 2, 2023
Galectin Therapeutics to Present Update on its Belapectin Liver Cirrhosis Program at the 20th Edition of Discovery on Target meeting, in Boston, September 25-28, 2023
September 25, 2023
Galectin Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference on September 13, 2023
September 10, 2023
Galectin Therapeutics to Present Data on Liver Cirrhosis at the 9th Edition of the Paris NASH meeting, at Institut Pasteur, September 7th & 8th 2023
September 6, 2023
Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2023 and Provides Business Update
August 13, 2023
Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2023 and Provides Business Update
May 14, 2023